Ownership
Public
Employees
~50
Therapeutic Areas
HematologyOncology
Stage
Phase 1
Modalities
Small molecule

Lorus Therapeutics General Information

Completed Phase 1 study in solid tumors with promising clinical activity. Planning Phase 1b study in hematologic malignancies.

Contact Information

Website
Primary Industry
Biotech
Corporate Office
Toronto, Ontario
Canada

Drug Pipeline

APTO-253
Phase 1
Indications: Lorem ipsum dolor sit
Modality: Lorem ipsum
Drug Asset 2
Phase X
Indications: Lorem ipsum dolor sit
Modality: Lorem ipsum
Drug Asset 3
Phase X
Indications: Lorem ipsum dolor sit
Modality: Lorem ipsum

For full access to Lorus Therapeutics's pipeline data

Book a demo

Key Partnerships

Need more data on over 80,000 life science companies, including over 1200 biotechs?

Book a demo

Lorus Therapeutics Funding

Deal TypeDateAmountStatusStage
Early Stage VC (Series A)04-Jun-2020$38MCompletedPhase 1
Seed Round12-Feb-2019$8.5MCompletedStartup

Interested in comprehensive profile data?

We'll help you find what you need

Learn more
To view Lorus Therapeutics's complete valuation and funding history, request access »